Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Aclaris Therapeutics' Non Operating Income fell 1213.17% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 3027.32%. This contributed to the annual value of $9.9 million for FY2024, which is 1595.96% up from last year.
  • Aclaris Therapeutics' Non Operating Income amounted to $2.5 million in Q3 2025, which was down 1213.17% from $3.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Non Operating Income high stood at $3.1 million for Q4 2024, and its period low was -$851000.0 during Q3 2021.
  • Moreover, its 5-year median value for Non Operating Income was $1.9 million (2024), whereas its average is $1.5 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Non Operating Income tumbled by 33865.98% in 2021 and then skyrocketed by 152247.19% in 2022.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Non Operating Income stood at $89000.0 in 2021, then soared by 1522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then surged by 42.67% to $3.1 million in 2024, then decreased by 18.83% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.